GH hormone replacement in adults risk-benefict analysis
Main Article Content
Abstract
Growth hormone deficiency is a clinical condition resulting from decreased secretion of growth hormone (GH), which leads to several disorders, so replacement therapy has been used as a treatment for over 30 years. The aim is to understand the negative and beneficial effects of GH replacement. Methodology: In this literature review, the MEDLINE, PUBMED and SCIENCE DIRECT databases were used with the descriptors “Hormone Replacement Therapy”, “pituitary growth hormone” and “Long Term Adverse Effects”, filters were applied from the last 10 years (2014 to 2024), full and free texts, and in the end, 14 works that addressed the theme were used. Among the positive effects of using GH replacement therapy, there is an improvement in body composition, physical fitness and muscle strength, an increase in bone mineral density, lipid profile and cardiovascular inflammatory markers. On the other hand, among the adverse effects, there may be hyperglycemia, insulin resistance, risk of neoplasia, peripheral edema, and hormonal axis dysregulation. From treatment with GH, it is seen that the adverse effects differ according to the patient's profile, highlighting age, gender, and pre-existing comorbidities, and therefore, an individualized assessment of the risks and benefits must be made, while the beneficial effects that the treatment offers are indisputable, and these are independent of the particularities of each patient, with proven improvement in quality of life and reduction of complications, concluding that the benefits outweigh the possible adverse effects that the patient may develop.
Article Details
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
• The author (s) warrant that the contribution is original and unpublished and that it is not in the process of being evaluated in other journal (s);
• The journal is not responsible for the opinions, ideas and concepts issued in the texts, as they are the sole responsibility of the author (s);
• Publishers have the right to make textual adjustments and to adapt the article to the rules of publication.
Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (eg publish in institutional repository or as book chapter), with acknowledgment of authorship and initial publication in this journal.
Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and citation of the published work (See The Effect of Free Access) at http://opcit.eprints.org/oacitation-biblio.html
How to Cite
References
KARGI, Y A. Impact of long-acting growth hormone replacement therapy in adult growth hormone deficiency: Comparison between adolescent, adult, and elderly patients. Best Practice & Research Clinical Endocrinology & Metabolism. Volume 37, Issue 6,
Disponivel em: https://pubmed.ncbi.nlm.nih.gov/37802712/ . Acesso em 05 de maio de 2025
CHRISTA C. van Bunderen, DANIEL S. Olsson. Meta-analysis of mortality in adults with growth hormone deficiency: Does growth hormone replacement therapy really improve mortality rates? Best Practice & Research Clinical Endocrinology & Metabolism. Volume 37, Issue 6, 2023. Disponivel em: https://www.sciencedirect.com/science/article/pii/S1521690X23001094 . Acesso em 05 de maio de 2025
CHRISTA C. van Bunderen; NADÈGE C. van Varsseveld; EVA Marie Erfurth; JOHANNES C.F. Ket, MADELEINE L. Drent. Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin Endocrinol (Oxf), 81(1): 1-14, 2014. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/24750271/ . Acesso em 05 de maio de 2025
DÍEZ, Juan J; SANGIAO-ALVARELLOS, Susana; CORDIDO, Fernando
Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks. International journal of molecular sciences vol. 19,3 893. 17 Mar. 2018. Disponivel em: https://pmc.ncbi.nlm.nih.gov/articles/PMC5877754/
. Acesso em 05 de maio de 2025
GASCO, Valentina; CAPUTO, Marina; LANFRANCO, Fabio; GHIGO, Ezio; GROTTOLI, Silvia. Management of GH treatment in adult GH deficiency. Best practice & research. Clinical endocrinology & metabolism vol. 31,1, 2017. Disponivel em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-28477728 . Acesso em 05 de maio de 2025
HÖYBYE, Charlotte. Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks. Best practice & research. Clinical endocrinology & metabolism vol. 37,6, 2023. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/37308376/
. Acesso em 05 de maio de 2025
JOHANNSSON, Gudmundur, TOURAINE, P..; FELDT-RASMUSSEN, U.; PICO, A.; VILA, G.; MATTSON, A.; CARLSSON, M.; KORBONITS, M.; BEEK, A.;
WAJNRAJCH, M.; GOMEZ, R.; YUEN, K. Long-term Safety of Growth Hormone in
Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients. The Journal of clinical endocrinology and metabolism vol. 107,7, 2022. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/35368070/ . Acesso em 05 de maio de 2025
NATASHA M. Appelman-Dijkstra, KIM M. J. A. Claessen, NEVEEN A. T. Hamdy, ALBERTO M. Pereira, NIENKE R. Biermasz. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with Growth Hormone Deficiency (GHD): The Leiden Cohort Study. Clin Endocrinol. 2014. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/24816144/ . Acesso em 05 de maio de 2025
PAN, hui; HONG-WEI, du. Safety considerations for the clinical application of recombinant human growth hormone. Zhongguo dang dai er ke za zhi. Chinese journal of contemporary pediatrics vol. 26,5, 2024. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/38802902/ . Acesso em 05 de maio de 2025
SHERWIN Criseno; GLEESON, Helena; TOOGOOD, Andrew; GITTOES, Neil; KARAVITAKI, Niki. Discontinuation of long-term growth hormone treatment in adults with growth hormone deficiency: a survey of UK practice. Endocrine Connections, Volume 13, Issue 5, 2024. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/38513362/ . Acesso em 05 de maio de 2025
TAKAHASHI, Yutaka; FATURADOR, B.; FUKUOKA, H.; HO, K.; RASMUSSEN, M; NEDJATIOAN, N.; YUEN, K.; JOHANNSSON, G. Weekly
somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency. Pituitary vol. 26,1, 2023. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/36380045/ . Acesso em 05 de maio de 2025
TESSA, N Slagboom; CHRISTA, C van Bunderen; AART, Jan van der Lely, MADELEINE L Drent. Sex Differences in Long-Term Safety and Tolerability of GH Replacement Therapy in GH Deficient Adults, The Journal of Clinical Endocrinology & Metabolism, Volume 108, Issue 7, July 2023. Disponivel em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-36652411 . Acesso em 05 de maio de 2025
YUEN, KCJ; MILLER, BS; BOGUSZEWSKI, CL; HOFFMAN, AR. Usefulness
and Potential Pitfalls of Long-Acting Growth Hormone Analogs. Frontiers in
endocrinology 12, 2021. Disponivel em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-33716988 . Acesso em 05 de maio de 2025
YUEN, Kevin C.J; BILLER, Beverly; RADOVICK, Sally; CARMICHAEL,
John; JASIM, Sina; PANTALONE; Kevin; HOFFMAN, Andrew. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care. Endocrine Practice, Volume 25, 2019. Disponivel em: https://www.sciencedirect.com/science/article/pii/S1530891X20351454 . Acesso em 05 de maio de 2025